Article

Alcon withdraws anecortave application

Fort Worth, TX?Alcon Inc. has withdrawn its application for European marketing authorization for anecortave acetate suspension for depot injection (Retaane) 30 mg/ml after being told that more clinical data would be necessary for approval.

Fort Worth, TX-Alcon Inc. has withdrawn its application for European marketing authorization for anecortave acetate suspension for depot injection (Retaane) 30 mg/ml after being told that more clinical data would be necessary for approval.

The company said in a prepared statement that the European Medicines Agency and the FDA had informed Alcon that it would need additional clinical data from existing and/or new clinical trials to support approval.

Alcon said it is revising its clinical strategy and plans to continue developing the drug for wet age-related macular degeneration in the United States, Europe, and key markets around the world. No timeframe was announced.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.